In this episode, TRC Healthcare editor, Sara Klockars, PharmD, BCPS unpacks the newly approved use of tirzepatide (Zepbound) for obstructive sleep apnea (OSA)—a first-in-class pharmacologic option for a condition long managed with devices and lifestyle changes.
You’ll hear a concise review of sleep apnea pathophysiology, how tirzepatide works to reduce airway obstruction, and what the latest clinical trials reveal about its efficacy and safety. Plus, you’ll get practical pharmacy-focused insights on side effect management, payer considerations, and how to avoid duplicate GLP-1 therapy.
This is an excerpt from our April 2025 Pharmacy Essential Updates continuing education webinar series.
The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:
Don’t miss out! Subscribe today to stay ahead with trusted insights and tools.
Use code podcast1025 at checkout for 10% off a new subscription.
🎓 Are you a student? Great news—students can access a free version of Pharmacist’s Letter.
****
GLP-1 Essentials from TRC Healthcare – Now Available
Master the essentials of GLP-1 therapy with this focused GLP-1 agonists CE bundle. Get 4 hours of CE plus clinical tools to help you prescribe, titrate, switch therapies, and support patients confidently.
Courses include:
Now included with Pharmacist’s Letter Platinum and Diamond subscriptions, or available as a standalone CE experience.
****
Email us: ContactUs@trchealthcare.com.
The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.
Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.
Learn more about our product offerings at trchealthcare.com.
